Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Hims & Hers Health’s second quarter results were met with a significant negative market reaction, as sales growth lagged Wall Street’s expectations despite a strong rise in non-GAAP profitability.

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

Through a trust, Dudum sold about $33.4 million worth of his company’s stock on Thursday, according to a filing with the ...

In separate filings, Chief Legal Officer Soleil Boughton sold 2,572 shares at a price of $51.64 apiece for $132,818, while ...

Insider moves in IonQ, Hims and Hers, Eli Lilly, and TransMedics reveal bold buys, record sales, and signals worth watching.

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 3.6% in the afternoon session after the ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

In separate filings, Chief Legal Officer Soleil Boughton sold 2,572 shares at a price of $51.64 apiece for $132,818, while ...

Andrew Dudum cofounded online pharmacy Hims & Hers eight years ago, when he was 27 years old. He’s now the latest to make a fortune off the popularity of weight loss injections.

"We're excited to take this moment to really accelerate both the European expansion, but also use this platform as an accelerant as we move into more markets," Hims & Hers CEO Andrew Dudum told ...